The combination of a MEK inhibitor with an inhibitor of the antiapoptotic BCL-XL led to increased apoptosis in many KRAS mutant cell lines from different histologies, and tumor regression in in vivo lung cancer mouse models (48). Here, KRAS is linked to lung carcinoma.